The principal objective of the Geisinger Clinical Oncology Program is to enroll a maximum number of participants onto NCI-approved cancer prevention, cancer control and cancer treatment protocols, and bringing research-quality cancer care to a large rural population of Pennsylvania. The Geisinger Health System (GHS) serves more than 2.5 million Pennsylvanians across 31 primarily rural counties in the central and northeastern parts of the State. This Health system includes a 556 physician primary and multispecialty group practice in 45 sites, anchored by three hubs: the 388 bed tertiary care Geisinger Medical Center in Danville, the 177 bed- hospital with 100-member multispecialty group in Wilkes-Barre and the 90-member multispecialty group in State College. New additions to the System over the past year include a 206 bed acute care hospital in Wilkes-Barre (Geisinger South Wilkes-Barre) and a large private oncology practice in Hazelton that our System acquired in June, 2007. Geisinger operates a health insurance provider with HMO and PPO products with 205,000 members that is research friendly and promotes cancer control and prevention activities. Geisinger's advantages include a strong, stable CCOP organization and staff with excellent retention, successful performance and high data quality over 24 years CCOP experience. GHS enjoys a large network of primary care practices, with all practices and all physicians (including hospital based specialists) linked by a totally paperless electronic medical records (EPIC-Care). Computerized patient management includes a System-wide IMPAC system for all chemotherapy and radiation therapy treatments, a System cancer registry (ONCOLOG) and a Protonet data management system for all cancer related clinical trials, available at all practice locations, and even to non-GHS private oncologists in our area. This CCOP proposal retains NCCTG as our primary research base, ECOG and RTOG as secondary bases, COG as our Children's base, and Fox Chase Cancer Center as a cancer prevention and control base. The relevance of this proposal to public health is that it ensures an otherwise large, rural underserved population the benefits of clinical trial participation, which has been shown to be associated with higher quality, more up-to-date cancer care. It provides a wide footprint of participation by community oncologists and helps to accelerate knowledge transfer resulting from clinical trials to our rural patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
St Germain, Diane
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Geisinger Clinic
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99
Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8

Showing the most recent 10 out of 115 publications